References
- ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J20144334337324337046
- ToTStanojevicSMooresGGlobal asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health20121220422429515
- PetersSPFergusonGDenizYReisnerCUncontrolled asthma: a review of the prevalence, disease burden and options for treatmentRespir Med20061001139115116713224
- PriceDWilsonAMChisholmAPredicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practiceJ Asthma Allergy2016911226793004
- TaliniDNovelliFBacciESputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational studyBMJ Open20155e005748
- BeldaJParameswaranKLemiereCKamadaDO’ByrnePMHargreaveFEPredictors of loss of asthma control induced by corticosteroid withdrawalCan Respir J20061312913316642226
- Benralizumab (FASENRA™) Prescribing Information2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdfAccessed January 10, 2018
- BleeckerERFitzGeraldJMChanezPEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialLancet20163882115212727609408
- FergusonGTFitzGeraldJMBleeckerERBenralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Respir Med2017556857628545978
- FitzGeraldJMBleeckerERNairPBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialLancet20163882128214127609406
- GoldmanMHirschIZangrilliJGNewboldPXuXThe association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studiesCurr Med Res Opin20173916051613
- HuynhTKOstergaardAEgsmoseCMadsenORPreferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritisPatient Prefer Adherence20148939924470758
- StonerKLHarderHFallowfieldLJJenkinsVAIntravenous versus subcutaneous drug administration. Which do patients prefer? A systematic reviewPatient201582145153
- SachaGRogersJAMillerRLPre-filled syringes: a review of the history, manufacturing and challengesPharm Dev Technol20152011125589433
- RomackerMSchoenknechtTForsterRPrefilled syringes: the container of choice for today’s injectablesONDrug Delivery200845
- FergusonGTMansurAJacobsJFunctionality, reliability, and performance of an accessorized pre-filled syringe with home administered subcutaneous benralizumab for adult patients with severe asthma [abstract]Am J Respir Crit Care Med2017195A3194
- JuniperEFBousquetJAbetzLBatemanEDCommitteeGIdentifying “well-controlled” and “not well-controlled” asthma using the Asthma Control QuestionnaireRespir Med200610061662116226443
- Stelara [package insert]Horsham, PAJanssen Biotech Inc.2012
- NairPWenzelSRabeKFOral glucocorticoid-sparing effect of benralizumab in severe asthmaN Engl J Med20173762448245828530840
- FitzGeraldJMBleeckerERMenzies-GowAPredictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studiesLancet Respir Med20186516428919200